✨ Free AI Report
ContraFect Corp: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview ContraFect Corp
Research Preview

ContraFect Corp: Business Overview, Financials & Competitive Analysis

ContraFect Corp was a clinical-stage biotechnology company focused on developing novel therapeutics for drug-resistant, life-threatening infectious diseases. The company pioneered direct lytic agents (lysins and amuri...

Analyst-debate audio for ContraFect Corp

AskCyborg analysts argue the bull and bear cases for ContraFect Corp across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
ContraFect Corp OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
2/ 10Challenged

Cyborg Score thesis

Once-promising lysin platform failed to achieve clinical-stage funding sustainability, resulting in...

Read the full analyst-debate transcript →
Industry Stem Cell Therapy
3 named competitors
1 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 7, 2026
AI-Verified Research
30+ Page Report

Get the Latest ContraFect Corp Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

ContraFect Corp Overview

Pro stress-test →

ContraFect Corp was a clinical-stage biotechnology company focused on developing novel therapeutics for drug-resistant, life-threatening infectious diseases. The company pioneered direct lytic agents (lysins and amurin peptides) as new medical modalities to combat antibiotic-resistant pathogens. However, the company filed for Chapter 7 liquidation in December 2023.

Strategic Profile

Pro stress-test →

ContraFect's innovation centered on bacteriophage-derived lysins targeting conserved bacterial regions resistant to mutation, with lead candidate exebacase (CF-301) for prosthetic joint infections and CF-370 for gram-negative pathogens. The company held a license agreement with The Rockefeller University for gram-negative lysin research. Operations ceased following liquidation filing.

Competitive Landscape

Pro stress-test →

ContraFect competed in the antibiotic resistance therapeutics space against traditional small-molecule antibiotic developers, monoclonal antibody platforms (Regeneron, GSK), and other novel modality companies (phage therapy platforms, antimicrobial peptides). Its differentiation through bacteriophage lysins offered a novel mechanism but failed to achieve regulatory or commercial success.

Industry Context

ContraFect Corp operates in Stem Cell Therapy.

Key facts

Founded: 2008 · Headquarters: Yonkers, US · Employees: 23 · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for ContraFect Corp.

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when ContraFect Corp has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

AicuronAntimicrobial peptides for resistant infections→Conventional AntibioticsTraditional antibiotic therapies→Monoclonal AntibodiesAntibody-based infectious disease therapeutics→

Compare ContraFect Corp with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

ContraFect Corp operates in Stem Cell Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Stem Cell Therapy research →
NEW · MCP server

Ask your AI assistant about ContraFect Corp

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare ContraFect Corp and its top competitor on Cyborg Score”
“What did ContraFect Corp do this quarter?”
“Is ContraFect Corp a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does ContraFect Corp do?+
ContraFect Corp was a clinical-stage biotechnology company focused on developing novel therapeutics for drug-resistant, life-threatening infectious diseases. The company pioneered direct lytic agents (lysins and amuri...
What is ContraFect Corp's Cyborg Score?+
ContraFect Corp has a Cyborg Score of 2/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are ContraFect Corp's main competitors?+
Named competitors include Aicuron, Conventional Antibiotics, Monoclonal Antibodies. The full competitive landscape is in the AskCyborg report.
How can I get the full ContraFect Corp research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the ContraFect Corp research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track ContraFect Corp over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.